Organization
Actuate Therapeutics, Inc.
4 abstracts
Abstract
Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Actuate Therapeutics, Inc., Courante Oncology,
Abstract
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Mayo Clinic, Actuate Therapeutics, Inc., Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Legorreta Cancer Center at Brown University,
Abstract
In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.Org: Lantern Pharma, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, Brown University Warren Alpert Medical School, Winship Cancer Institute of Emory University, DTC,
Abstract
Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer.Org: Legorreta Cancer Center, Winship Cancer Institute of Emory University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, DTC, Actuate Therapeutics, Inc.,